Intercept Pharmaceuticals CEO Mark Pruzanski's 2020 pay slips 3% to $6.4M
Intercept Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 27, 2021
Intercept Pharmaceuticals reported fiscal year 2020 executive compensation information on April 27, 2021.
In 2020, seven executives at Intercept Pharmaceuticals received on average a compensation package of $3M, a 19% decrease compared to previous year.
Average pay of disclosed executives at Intercept Pharmaceuticals
Mark Pruzanski, Chief Executive Officer, received $6.4M in total, which decreased by 3% compared to 2019. 64% of Pruzanski's compensation, or $4.1M, was in stock awards. Pruzanski also received $532K in non-equity incentive plan, $1M in option awards, $758K in salary, as well as $7.7K in other compensation.
For fiscal year 2020, the median employee pay was $267,493 at Intercept Pharmaceuticals. Therefore, the ratio of Mark Pruzanski's pay to the median employee pay was 24 to one.
Jerome Durso, Chief Operating Officer, received a compensation package of $3.9M, which decreased by 9% compared to previous year. 53% of the compensation package, or $2.1M, was in stock awards.
Sandip Kapadia, Chief Financial Officer, earned $2.3M in 2020, a 1% decrease compared to previous year.
Richard Kim, Former President, U.S. Commercial & Strategic Marketing, received $2.3M in 2020, which decreases by 6% compared to 2019.
Lisa Bright, Former President, International, earned $2.2M in 2020.
Ryan Sullivan, General Counsel, received $2.1M in 2020, which decreases by 30% compared to 2019.
Christian Weyer, M.D., M.A.S, EVP, Research & Development, earned $2.1M in 2020.
Related executives
Mark Pruzanski
Intercept Pharmaceuticals
Chief Executive Officer
Jerome Durso
Intercept Pharmaceuticals
Chief Executive Officer
Sandip Kapadia
Intercept Pharmaceuticals
Chief Financial Officer
Richard Kim
Intercept Pharmaceuticals
Former President, U.S. Commercial & Strategic Marketing
Lisa Bright
Intercept Pharmaceuticals
Former President, International
Ryan Sullivan
Intercept Pharmaceuticals
General Counsel
Christian MAS
Intercept Pharmaceuticals
EVP, Research & Development
You may also like
Source: SEC filing on April 27, 2021.